THC Therapeutics, Inc.

As of July 31, 2024, THC Therapeutics, Inc. carries a market capitalization of 23,319.69, placing it among publicly traded companies globally. Its enterprise value stands at 755,899.69, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2024, THC Therapeutics, Inc. has 38.87M shares outstanding.

These figures are as of July 31, 2024.

As of July 31, 2024, THC Therapeutics, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -19.25, indicating conservative leverage, while an interest coverage ratio of -3.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended July 31, 2024. Return on assets (ROA) is negative at -6,866.59, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, THC Therapeutics, Inc.'s stock has gained approximately 300.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.00.

Over the twelve months ended July 31, 2024, THC Therapeutics, Inc. generated - - in revenue and converted that into -811,562.00 in net income, yielding earnings per share of -0.02. EBITDA reached -540,578.00, while operating income came in at -541,975.00.

As of July 31, 2024, THC Therapeutics, Inc. holds 35.00 in cash and equivalents against 731,789.00 in total debt, resulting in a net debt position of 731,754.00. Total book value stands at -3.80M, with working capital of -3.81M providing operational flexibility.

THC Therapeutics, Inc. produced -183,273.00 in operating cash flow over the twelve months ended July 31, 2024.

These figures cover the twelve months ended July 31, 2024. Free cash flow yield is negative at -847.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -786.02, meaning THC Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

THC Therapeutics, Inc.'s most recent stock split took place on December 10, 2018 with a 10:1 split ratio.

As of July 31, 2024, THC Therapeutics, Inc. has an Altman Z-Score of -1.75M, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.